Sucroferric oxyhydroxide

Drug Profile

Sucroferric oxyhydroxide

Alternative Names: Ferric oxyhydroxide; Ferrihydrite; Iron oxyhydroxide; P-TOL; PA-21; PA21-1; Phosphate binder - Vifor Pharma; Polynuclear iron(III)-oxyhydroxide; Velphoro

Latest Information Update: 07 Jan 2017

Price : $50

At a glance

  • Originator Vifor Pharma
  • Developer Fresenius Medical Care; Kissei Pharmaceutical; Vifor Fresenius Medical Care Renal Pharma; Vifor Pharma
  • Class Ferric compounds; Hyperphosphataemia therapies
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 01 Oct 2016 Hyogo College of Medicine and Kissei Pharmaceutical initiate a clinical trial for Hyperphosphataemia (in patients with chronic kidney disease on maintenance haemodialysis) in Japan (UMIN000023700)
  • 01 Sep 2016 Phase-III clinical trials in Hyperphosphataemia (Treatment-experienced) in Japan (PO) (UMIN000023657)
  • 01 Jun 2016 Phase-III clinical trials in Hyperphosphataemia (In infants, In children, In adolescents) in USA, Lithuania (PO, chewable tablet) (NCT02688764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top